NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) population analysis Neurofilament biomarker results...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials